Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q8IV63
UPID:
VRK3_HUMAN
Alternative names:
Serine/threonine-protein pseudokinase VRK3; Vaccinia-related kinase 3
Alternative UPACC:
Q8IV63; A6NEG5; A8KA53; Q502Y2; Q9P2V8
Background:
Inactive serine/threonine-protein kinase VRK3, also known as Serine/threonine-protein pseudokinase VRK3 and Vaccinia-related kinase 3, plays a pivotal role in cellular processes by suppressing ERK activity. It achieves this through promoting the phosphatase activity of DUSP3, which specifically dephosphorylates and inactivates ERK in the nucleus.
Therapeutic significance:
Understanding the role of Inactive serine/threonine-protein kinase VRK3 could open doors to potential therapeutic strategies.